Catalog No.: PC-20661Not For Human Use, Lab Use Only.
BAY 55-9837 is a potent, highly selective peptide agonist of vasoactive intestinal peptide receptor 2 (VIPR2, VPAC2 receptor) with Kd of 0.65 nM, >100-fold selectivity over VPAC1.
BAY 55-9837 is a potent, highly selective peptide agonist of vasoactive intestinal peptide receptor 2 (VIPR2, VPAC2 receptor) with Kd of 0.65 nM, >100-fold selectivity over VPAC1. BAY 55-9837 stimulated glucose-dependent insulin secretion in isolated rat and human pancreatic islets, increased insulin synthesis in purified rat islets, and caused a dose-dependent increase in plasma insulin levels in fasted rats (EC50=3 pM/kg). Bay 55-9837 reduced the glucose area under the curve following an intraperitoneal glucose tolerance test. Bay 55-9837 increases neuronal damage and hemorrhagic transformation after stroke in type 2 diabetic rats.
Physicochemical Properties
M.Wt
3342.20
Formula
C148H239ClN44O42
Appearance
Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility
10 mM in DMSO
Chemical Name/SMILES
Peptide HSDAVFTDNYTRLRKQVAAKKYLQSIKNKRY
References
1. Tsutsumi M, et al. Diabetes. 2002 May;51(5):1453-60.
2. Hadwen J, et al. Orphanet J Rare Dis. 2014 Jan 9;9:4.
3. Darsalia V, et al. Neuropeptides. 2013 Apr;47(2):133-7.
4. Pan CQ, et al. J Pharmacol Exp Ther. 2007 Feb;320(2):900-6.
